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Copyright © 200? JCBN 200? This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unre- stricted use, distribution, and reproduction in any medium, pro- vided the original work is properly cited. The purpose of this study was to investigate the effects of
supplementation with amino acids and vitamins on health condi 
tions in unhealthy older people. One bedridden inpatient group
(n = 10; mean age, 79.8 ± 8.5 y) and one outpatient group (n =9 ;
mean age, 72.9 ± 12.2 y) participated in this study. A mixture
supplementation with amino acids containing arginine (500 mg/
day), glutamine (600 mg/day), and leucine (1200 mg/day), and 11
kinds of vitamins was daily administrated for 8 weeks. In both
groups, general blood biomarkers such as white blood cell count,
natural killer cell activity, and C reactive protein levels were mea 
sured. All measurements were taken before (baseline), at 4 weeks
(mid point), and after each trial (post point). At mid point, natural
killer cell activity in the outpatient group increased significantly
compared to baseline. At post point, natural killer cell activity
in the outpatient and inpatient groups increased significantly
compared to baseline. The other blood biomarkers did not show
any significant change throughout the trial. This pilot study
suggested  that a mixture of arginine, glutamine, leucine, and
vitamins is useful to support innate immunity in unhealthy older
people, even if their diseases, symptoms, and prescribed medicines
are different.
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Introduction As people age, the incidence of age-related health diseases
such as cerebral infarction, cardiovascular disease, and
diabetes increases. Besides these primary diseases, aging is also
associated with attenuation of the immune system.(1,2) While
medical care for primary diseases is important, support for the
immune system is also required in the elderly patients. Because
many of them already take a variety of medicines for their primary
diseases, most would prefer not to take more.
Nutritional supplementation with amino acids and vitamins has
been shown to affect immune variables. Glutamine and arginine
are thought to be good candidates for immune system support.(3,4)
Glutamine is the most abundant free amino acid in blood and
constitutes more than 50% of the amino acid pool in human skeletal
muscle. Macrophages and lymphocytes contributing to the immune
system require glutamine as a fuel.(5) It has been observed that
glutamine causes neutrophils to increase their phagocytic activity
in a dose-dependent manner.(6) Glutamine is also utilized as a
major fuel source by intestinal mucosal cells and influences the
gut-associated immune system.(7–9) In an in vitro study, glutamine
decreased the tumor necrosis factor α-mediated bacterial trans-
location in enterocytes.(10) Another in vivo study demonstrated that
glutamine-supplemented rat group with an obstructed terminal
ileum had fewer positive cultures in blood after injection of E coli
into the ileal lumen.(11) Although glutamine is not an essential
amino acid, it is considered to be a conditionally essential amino
acid because its plasma levels decrease sharply when people are
critically ill.(12,13) Arginine is also a nonessential amino acid, but
has been reported to become conditionally essential in the
critically ill.(14,15) It has been observed that arginine prevents
thymic involution after surgery and increases the number of
lymphocytes. Therefore, it acts as a potent modulator of immune
function.(16–18) Several studies have demonstrated that arginine
intake improves T-cell activity, neutrophil chemotaxis, and natural
killer (NK) cytotoxicity.(4,19–21) Moreover, multivitamin, including
vitamin C and E, is known to improve immunity.(22) It has been
observed that various types of diseases such as cancer and
hypertension produce reactive oxygen species that impair immune
function.(23–25) Therefore, antioxidant effects of vitamins are
thought to be beneficial for maintenance of the immune function.
In addition to attenuation of immune function, involuntary loss
of muscle mass with aging (sarcopenia) is also a serious problem
for maintaining a quality of life. Although resistance exercise
programs are recommended for the elderly to prevent sarcopenia,
it is difficult for them to engage in these because many of them
suffer from multiple diseases. Therefore, nutritional approaches to
prevent sarcopenia have been evaluated. It has been observed that
leucine, an essential amino acid, activates intracellular kinases
linked to the translation of proteins such as those associated with
the mammalian target of rapamycin signaling pathway, which
includes the 70-kDa ribosomal protein S6 kinase and eukaryotic
initiation factor 4E-binding protein 1, leading to stimulation of
muscle protein synthesis.(26–29) It has been observed that supple-
mentation with a high proportion of leucine in an oral mixture of
essential amino acids resulted in an additional 0.008% per hour
increase in the postprandial muscle protein synthetic rate for 2.5 h
in healthy older men.(30)
Based on these studies, we hypothesized that supplementation
with a mixture of glutamine, arginine, leucine, and vitamins may
have beneficial health effects on the elderly in poor health.
Methods
Bedridden inpatients. Thirteen bedridden inpatients (7 males,
6 females; mean age, 81.8 ± 8 years) participated in this study. The
hospitalized duration of the bedridden inpatients was 16.4 ± 7.6
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months. All participants were Japanese; their health status and the
prescription drugs they were taking are summarized in Table 1.
Eleven of 13 bedridden inpatients underwent percutaneous endo-
scopic gastrostomy (PEG). Three bedridden inpatients dropped
out for the following reasons: 1 (female) had gastritis, 1 (male) had
pneumonia, and 1 (male) was moved to another hospital. Doctors
confirmed that the causes of discontinuance were not attributed to
this trial.
Table 1. Health status and prescription drugs
participant health status prescription drugs trial
bedridden inpatients
A a sequela of brain stem hemorrhage, right gastric cancer ranitidine hydrochloride, polaprezinc, theophylline, 
carbocysteine, magnesium oxide, pravastatin sodium, 
clarithromycin
completed
B after septicemia, a sequela of cerebral infarction polaprezinc, lactobacilli, sodium ferrous citrate, 
brotizolam
completed
C a sequela of cerebral infarction sodium picosulfate hydrate, amlodipine besylate completed
D a sequela of cerebral infarction, type 2 diabetes sodium valproate, carbocysteine completed
E a sequela of brain hemorrhag digoxin, famotidine, brometon, magnesium oxide, 
famotidine, lactobacilli
completed
F after acute subdural hematoma carbocysteine, ranitidine hydrochloride, lactobacilli dropped out
G type 2 diabetes, a sequela of cerebral infarction, 
obsolete myocardial infarction
nitroglyerin, tiapride hydrochloride, mosapride citrate completed
H obsolete myocardial infarction, chronic respiratory failure, 
a sequela of cerebral infarction
aspirin, famotidine, furosemide, magnesium oxide, 
ticlopidine hydrochloride, amlodipine besylate, 
spironolactone, pravastatin sodium, sennoside, 
epinastine hydrochloride, salmeterol xinafoate
dropped out
I general prostration, depression, spondylosis deformans fluticasone propionate, carbocysteine, 
tiotropium bromide hydrate, clarithromycin, sulpiride
completed
J right nephrosclerosis, left ureter cancer, 
left brain stem hemorrhage
aspirin, lactobacilli, zopiclone, sodium picosulfate, 
proctosedyl
completed
K cerebellar infarction, hypertension, 
aspiration pneumonia, reflux esophagitis
lactobacilli, omeprazole, mosapride citrate, 
efonidipine hydrochloride
dropped out
L type 2 diabetes, pressure sore of sacral region, 
refractory pneumonia
enalapril maleate, aspirin, nizatidine completed
M malignant lymphoma, chronic gastritis sodium valproate, ursodeoxycholic acid, yokukansan, 
antibiotic resistant lactic acid bacteria
completed
outpatients
N prostate cancer, a sequela of cerebral infarction, 
after implant of pacemaker
amlodipine besylate, ranitidine hydrochloride, 
troxipide, pravastatin sodium, zopiclone, furosemide, 
magnesium oxide, allopurinol, digoxin, glybenclamide, 
aspirin
dropped out
O angina pectoris, paroxysmal tachycardia, 
after surgery of colon cancer, atrial extrasystole
tocopherol nicotinate, dipyridamole, isosorbide dinitrate, 
brotizolam, nitroglyerin, sodium ferrous citrate, 
zolpidem tartrate
completed
P left ventlicular hypertrophy, anemia after surgery 
of gastric cancer, refractory pneumonia
diazepam, fursultiamin, mecobalamin, omeprazole, 
polaprezinc, brotizolam, itoprode hydrochloride, 
sennoside
completed
Q chronic gastritis, impairment of liver function, 
hyperlipemia
azulene sulfonate sodium, vitamin B compound dropped out
R hypertension, ventricular extrasystole, 
overactive bladder non neurogenic overactive bladder
tamsulosin hydrochloride, hachimijirogan, 
fexofenadine hydrochloride, mexiletine hydrochloride, 
valsartan
completed
S type 2 diabetes, iron deficiency anemia, 
diabetic peripheral neuropathy
mecobalamin, valsartan, epalrestat, cilnidipine, 
pioglitazone hydrochloride
completed
T type 2 diabetes, diabetic nephropathy, 
iron deficiency anemia
kalliginogenase, voglibose, fluvastatin sodium, 
ranitidine hydrochloride, plaunotol, 
difenidol hydrochloride, disopyramide
completed
U iron deficiency anemia, hypertension losartan completed
V cerebral infarction, hepatitis type C, liver cirrhosis, 
hypertension
aspirin, quinapril hydrochloride, doxazosin mesilate, 
enalapril maleate, trichlormethiazide, nifedipine, 
ranitidine hydrochloride, troxipide, sennoside, 
loratadine
completed
W iron deficiency anemia Not prescripted completed
X type 2 diabetes, diabetic peripheral neuropathy glybenclamide, alfacalcidol, ranitidine hydrochloride, 
flurbiprofen, azulene sulfonate sodium
completeddoi: 10.3164/jcbn.11 55
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Outpatients. Eleven outpatients (7 males, 4 females; mean
age, 74 ± 12 years; body mass index, 21.0 ± 3.7) from the Sansei
Hospital (Hyogo Prefecture, Japan) participated in this study. The
duration of ambulatory visits to the hospital for the outpatients was
117.6 ± 64.0 months. All participants were Japanese; their health
status and the prescription drugs they were taking are summarized
in Table 1. Two male outpatients dropped out, 1 because of
hospitalization (worsening of prostate cancer) and 1 because of a
bone fracture. Doctors confirmed that the causes of discontinuance
were not attributed to this trial.
Experimental procedures. Administering a placebo to
patients as a control group was not agreeable to them and their
families. Therefore, in this study we could not set the placebo
group. All experimental procedures were performed in accordance
with the Declaration of Helsinki. All participants and their
families were informed about the experimental procedures and
purpose of the study, and they gave written informed consent
prior to participation. The ethics committee of the Sansei Hospital
approved this study. The duration of this study was 8 weeks.
Diet and supplementation programs for the bedridden
inpatients. The bedridden inpatient participants were admin-
istered a liquid diet (Isocal 2K, Nestle Nutrition Co., Tokyo, Japan)
twice (morning and evening) daily. The composition of the diet is
presented in Table 2. The amount of the liquid diet was determined
by medical doctors according to the participants’ health conditions
(mean total calorie, 1147 ± 334 kcal/day; mean protein intake,
39.0 ± 11.3 g/day). A powder containing amino acids and vitamins
was mixed in the diet. To avoid malabsorption, the powder was
mixed with each of the two daily doses of the liquid diet. The
composition of the supplementation is presented in Table 3. This
composition was based on our previous studies in which it
improved health conditions in young male athletes.(31,32)
Diet and supplementation programs for the outpatients.
The same amino acid and vitamin supplementation as the inpatients
was administered to the outpatients with water twice daily,
immediately after dinner and before sleeping. Because they
already took a variety of medicines with water for their primary
diseases from morning to evening, to avoid satiety, most of them
preferred to take the supplementation at evening and before sleep.
When the supplementation was administered to the outpatients,
they recorded it on a check sheet. The researchers subsequently
confirmed the compliance of their supplementation programs. The
daily diet of the outpatients was almost the same throughout the
trial period except for the additional amino acid and vitamin
supplementation. Their habitual nutrient intake was analyzed
using food-frequency questionnaires.(33)
Anthropometric evaluation. Initially, the outpatient partic-
ipants were subjected to anthropometric evaluation. The anthropo-
metric evaluation included height, body weight, and body
composition comprising fat and lean body mass. Body composi-
tion was evaluated by bioimpedance (X-Scan plus, Owa Medical
Co., Fukuoka, Japan). This system applies to a constant current of
100 μA at 1, 5, 50, 250, and 550 kHz, and 280 μA at 1000 kHz
thorough the body. Subjects restrained from vigorous exercise
and alcohol intake during 24 h, preceding the measurements. The
room temperature was kept at 23°C. Bioimpedance measurements
of whole body were theoretically based on a previous study.(34) The
participants did not agree to using computed tomography and
dual energy X-ray absorptiometry to evaluate body composition
owing to concerns of radiation exposure. Anthropometric evalua-
tions were not performed for bedridden inpatients because they
faced difficulty in standing.
Blood sampling and measurement of body temperature.
Fasting venous blood samples were collected from each subject at
least 24 h before the trial (baseline), on the last day of the 4-week
(mid-point) period and on the last day of the 8-week (post-point)
period. The body temperature of bedridden inpatients was
measured daily. The number of days on which had a fever above
37°C was counted and the frequency (febrile frequency, the
number of days for which body temperature was more than
37°C/the number of days per month ×100) was compared with that
of control inpatients (n = 11) who did not participate in this study
but were hospitalized in the same room as the participating
inpatients. The control inpatients underwent PEG and were
administered the same liquid diet as the inpatient participants
(mean total calorie, 1140 ± 134 kcal/day; mean protein intake,
38.8 ± 5.0 g/day).
Blood analyses. Complete blood count and hematocrit
were analyzed using an automated hematology analyzer (Coulter
Electronics, Hialeah, FL). Concentrations of total plasma proteins,
serum albumin, blood urea nitrogen, serum creatinine, and serum
amylase activity were determined by routine methods. Serum
aspartate aminotransferase, alanine aminotransferase, leucine
aminopeptidase, cholinesterase, gamma-glutamyltranspeptidase,
and total bilirubin levels were used as liver function markers
Table 2. Liquid diet composition/pack (2000 kcal/1000 ml)
carbohydrate (g) 246 minerals (mg) vitamins amino acids (g)
fat (g) 86 potassium 1496 vitamin A (µg) 1496.3 isoleucine 3.2 arginine 2.1
sodium (g) 0.5 calcium 1103 vitamin B1 (mg) 4.0 leucine 6.0 glycine 1.2
dietary fiber (g) 1.7 magnesium 359 vitamin B2 (mg) 4.62 lysine 5.0 alanine 1.9
water 700 mL phosphorus 1148 vitamin B6 (mg) 5.04 methionine 1.8 serine 3.7
iron 25.0 vitamin B12 (µg) 1.0 cystine 0.2 aspartic acid 4.6
zinc 18.90 vitamin C (mg) 349.7 phenylalanine 3.4 glutamate 14.7
copper 3.0 vitamin D (µg) 9.98 tyrosine 2.7 proline 7.2
manganese 0.16 vitamin E (mg) 18.0 threonine 2.8
chlorine 998 niacin (mg) 53.9 tryptophan 0.8
selenium (µg) 89.8 folic acid (µg) 399.0 valine 4.1
pantothenic acid (mg) 25.0 histidine 2.0
Table 3. Amino acid and vitamin composition/pack
amino acid (mg) vitamin (mg)
arginine 250 vitamin A 0.45
glutamine 300 vitamin B1 1.4
leucine 600 vitamin B2 1.6
vitamin B6 2.0
vitamin B12 0.004
vitamin C 170
vitamin D 0.005
vitamin E 8.0
niacinamide 11.0
folic acid 0.4
pantothenic acid 5.5 J. Clin. Biochem. Nutr. | March 2012 | vol. 50 | no. 2 | 165
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and measured by routine methods. C-reactive protein (CRP) level
was used as an inflammation marker and measured using a latex
agglutination immunoassay (EIKEN Chemical, Co. Ltd., Tokyo,
Japan). To measure the in vitro tumoricidal activity of NK cells,
cytotoxicity was measured by determining the amount of 51Cr
released from target cells at an effector : target (E/T) ratio of
20:1.(35) Blood samples were centrifuged at 1500 × g (20°C) for
20 min and then 200 μL of prepared lymphocyte cells (1 × 106
cells/ml) and 10 µL of prepared K562 human chronic myelogenous
leukemia cells (1 × 106 cells/ml) labeled with 51Cr were added to
a plate. The plate was then incubated for 3.5 h at 37°C in an
atmosphere of 5% CO2. Following incubation, the activity of
NK cells was counted using a scintillation counter (Perkin Elmer
Japan Co. Ltd., Kanagawa, Japan).
Statistical analysis. The data of dropped out participants
were excluded from the data analyses. All data were expressed as
mean ± SD. The differences between the variables were examined
by one-way analysis of variance (ANOVA), followed by Fisher’s
protected least significant difference post-hoc test. Body tempera-
ture data were examined using 2 (condition) ×2 (time of measure-
ment) ANOVA for interaction and main effects. When a statistical
significance was obtained, Student’s t test was used to compare
the 2 groups and for comparisons within the same group. Statistical
significance was accepted at the p = 0.05 level.
Results
The outpatients mean habitual nutrient intake was 34.1 ± 3.8
kcal/kg/day including 1.27 ± 0.32 g protein/kg/day. Body weight
and body composition in the outpatients did not change
throughout the trial (Fig. 1a). At mid-point, NK cell activity in the
bedridden inpatients tended to increase compared to baseline
(p = 0.08), and at post-point, it increased significantly compared
to baseline (p = 0.03) (Fig. 1b). At mid-point (p = 0.01) and post-
point (p = 0.001), NK cell activity in the outpatients increased
significantly compared to baseline (Fig. 1b). The other biomarkers
did not change throughout the trial (Table 4). Febrile frequency in
the bedridden inpatients did not change throughout the trial,
whereas at the second month in the control inpatients, it increased
significantly compared to the first month (p = 0.03) (Fig. 2).
Febrile frequency did not show a condition × time interaction.
Discussion
In this study, we investigated whether supplementation of a
combination of glutamine, arginine, leucine, and 11 kinds of
vitamins had beneficial effects on the health of older people in
poor health. The aging process in humans results in sarcopenia,
which involves loss of skeletal muscle mass and function leading
to metabolic diseases such as obesity and type 2 diabetes.(36,37) To
improve body composition, older outpatients in this study were
administered a powder containing leucine because it activates
muscle protein synthesis. It has been shown that ingestion of 6.7 g
of essential amino acids containing 2.75 g of leucine increases
muscle protein synthesis (increase of 0.008% per hour) in younger
and older people.(30) The outpatients in this study were each
administered 600 mg of leucine immediately after dinner and
before sleeping. Because the outpatients had dinner every evening,
it was thought that total leucine intake over a short duration in
the evenings was at least above 1.2 g. Extrapolation of these data
toward the effect of leucine supplementation with dinner for 8
weeks would theoretically result in almost a 0.3 kg gain in muscle
mass. However, an 8-week period of leucine supplementation did
not increase lean body mass in the outpatients (Fig. 1a). It has been
shown that ingestion of 6.7 g of essential amino acids containing
2.75 g of leucine increased muscle protein synthesis, whereas
7.5 g/day of leucine supplementation for 3 months did not induce
any changes in the muscle mass and strength of healthy elderly
Fig. 1. Changes in body composition (a). Throughout the clinical trial,
body weight (BW), lean body mass (LBM), and fat mass (FM) in the
outpatients did not change with amino acid and vitamin supple 
mentation. NK cell activity in the inpatient and outpatient groups
increased with amino acid and vitamin supplementation (b).
Fig. 2. Febrile frequency (the number of days for which body temper 
ature was more than 37°C/the number of days per month ×100).doi: 10.3164/jcbn.11 55
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people.(30,38) However, it is thought that muscle protein synthesis is
influenced by daily total protein or leucine intake. A daily protein
intake above 0.85 g protein/kg body weight is adequate for older
people.(39) It has been shown that muscle mass does not increase in
subjects whose habitual protein intake is approximately 78 g/day,
even if administered 7.5 g/day of leucine for 3 months.(38) The
outpatients daily protein intake in this study was above 0.85 g
protein/kg body weight. Therefore, we can speculate that the
outpatients had adequate daily intake of protein and associated
leucine. Moreover, the outpatients also had severe diseases.
Therefore, their daily physical activity was low, which may have
countered the leucine-induced muscle protein synthesis response
even if daily intake of protein was adequate and leucine intake
increased muscle protein synthesis. To increase muscle mass of
older people in poor health, it might be necessary to increase
physical activity and leucine intake associated with more physical
activity.
Immune parameters were also evaluated in this study. Of
these, NK cell activity, an index of innate immunity, increased
in the outpatients and inpatients (Fig. 1b). In the immune system,
NK cell activity is thought to be one of the important indices for
monitoring immunity because innate immunity is the first line of
defense against infections. It has been shown that NK cell activity
is impaired due to various stressors, such as chronic heart failure(40)
Table 4. Hematological and biochemical parameters
Group baseline mid point post point
erythrocyte (million/µl) inpatients 3.97 ± 0.74 4.02 ± 0.63 4.04 ± 0.59
outpatients 3.97 ± 0.25 3.89 ± 0.28 3.87 ± 0.21
hemoglobin (g/dl) inpatients 12.22 ± 2.04 12.37 ± 1.77 12.52 ± 1.53
outpatients 11.92 ± 1.32 11.73 ± 1.48 11.61 ± 1.24
Ht (%) inpatients 38.0 ± 6.2 38.5 ± 5.4 38.8 ± 4.9
outpatients 36.8 ± 3.2 36.8 ± 3.5 36.4 ± 3.0
platelet (thousand/µl) inpatients 243.4 ± 42.8 240.6 ± 44.1 248.8 ± 38.0
outpatients 218.1 ± 63.9 209.2 ± 5.87 216.7 ± 70.5
leukocyte (/µl) inpatients 7320 ± 1530 7860 ± 1680 7310 ± 1290
outpatients 5230 ± 1260 5120 ± 1070 4820 ± 870
basophilic leukocyte (%) inpatients 0.50 ± 0.37 0.63 ± 0.60 0.67 ± 0.56
outpatients 0.64 ± 0.30 0.50 ± 0.32 0.49 ± 0.36
neutrophilic leukocyte (%) inpatients 52.54 ± 8.87 57.72 ± 10.04 54.26 ± 7.63
outpatients 56.76 ± 13.47 56.66 ± 12.52 53.37 ± 12.86
acidophilic leukocyte (%) inpatients 6.11 ± 7.32 5.88 ± 7.04 5.97 ± 6.62
outpatients 2.36 ± 1.71 2.07 ± 1.35 2.08 ± 1.44
lymphocyte (%) inpatients 34.30 ± 4.72 28.36 ± 5.66 32.51 ± 5.07
outpatients 33.80 ± 12.88 34.46 ± 10.80 36.62 ± 12.51
monocyte (%) inpatients 6.55 ± 1.95 7.21 ± 2.28 6.59 ± 1.40
outpatients 6.44 ± 1.07 6.32 ± 1.78 7.44 ± 2.64
total plasma protein (g/dl) inpatients 6.98 ± 0.58 7.01 ± 0.62 7.07 ± 0.54
outpatients 7.12 ± 0.56 7.13 ± 0.54 7.10 ± 0.44
albumin (g/dl) inpatients 3.58 ± 0.29 3.62 ± 0.31 3.64 ± 0.24
outpatients 4.12 ± 0.23 4.11 ± 0.34 4.14 ± 0.29
total bilirubin (mg/dl) inpatients 0.29 ± 0.09 0.35 ± 0.14 0.35 ± 0.15
outpatients 0.61 ± 0.23 0.56 ± 0.13 0.56 ± 0.11
aspartate aminotransferase (IU/L) inpatients 28.70 ± 15.05 36.00 ± 23.71 23.20 ± 5.49
outpatients 29.22 ± 18.98 25.44 ± 5.29 27.33 ± 6.56
alanine aminotransferase (IU/L) inpatients 20.20 ± 13.81 32.70 ± 28.28 20.70 ± 10.09
outpatients 22.78 ± 21.24 19.11 ± 6.19 20.33 ± 8.03
leucine aminopeptidase (IU/L) inpatients 45.00 ± 11.05 47.89 ± 14.15 47.00 ± 12.76
outpatients 38.89 ± 5.23 38.67 ± 4.61 38.89 ± 2.89
cholinesterase (IU/L) inpatients 3772 ± 940 3770 ± 821 3940 ± 836
outpatients 3754 ± 637 3722 ± 816 3798 ± 775
gamma glutamyltranspeptidase (IU/L) inpatients 30.40 ± 23.19 38.30 ± 28.74 35.50 ± 31.87
outpatients 16.89 ± 6.47 16.78 ± 6.94 16.67 ± 4.61
blood urea nitrogen (mg/dl) inpatients 21.80 ± 7.97 22.80 ± 9.60 23.10 ± 8.20
outpatients 15.44 ± 3.97 16.22 ± 4.89 16.11 ± 3.37
serum creatinine (mg/dl) inpatients 0.63 ± 0.18 0.61 ± 0.15 0.67 ± 0.20
outpatients 0.73 ± 0.18 0.75 ± 0.21 0.76 ± 0.21
serum amylase (IU/L) inpatients 90.90 ± 33.00 85.80 ± 32.58 84.40 ± 31.44
outpatients 97.11 ± 51.61 97.44 ± 45.45 100.33 ± 16.92
CRP (mg/dl) inpatients 1.02 ± 1.79 1.18 ± 1.21 1.38 ± 2.81
outpatients 0.29 ± 0.52 0.06 ± 0.06 0.04 ± 0.04 J. Clin. Biochem. Nutr. | March 2012 | vol. 50 | no. 2 | 167
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and high-intensity physical exercise.(41) Moreover, it has been un-
derstood that NK cell activity is mediated, at least partially, by ni-
tric oxide-mediated pathways.(42,43) Therefore, it is thought that ar-
ginine has a positive effect on NK cell activity because it is the
only biosynthetic substrate for nitric oxide. In vitro(42) and in vivo(4)
studies have shown that arginine administration enhances NK cell
activity. The participants in this study were administered 3 kinds
of amino acids. Although the relative efficacy of increased NK cell
activity is difficult to estimate, arginine might have been a key
factor in this result. The febrile frequency in the control inpatients
showed a variation between the first and second halves of the trial,
whereas that of the bedridden inpatients was stable throughout
(Fig. 2). This result implies that the innate immune system of the
inpatients who were administered amino acids was stable due to
increased NK cell activity.
Glutamine is the most abundant free amino acid in the human
body. It is known to be a conditionally essential amino acid
because its plasma levels decrease severely when people are
critically ill.(12,13) Nosocomial infections can cause severe clinical
problems in older inpatients. To prevent these infections, restora-
tion of immune and gut-barrier functions is important.(44) It has
been shown that glutamine supplementation increases lymphocyte
count and T-lymphocyte response in surgical patients in addition
to improving intestinal immune cell function.(45) In this study,
glutamine supplementation did not increase leukocyte, lymphocyte,
and monocyte counts (Table 4). Although the participants showed
increased NK cell activity, and the febrile frequency of the
inpatients was stable, our limited data did not show whether
these results were directly or indirectly influenced by glutamine
supplementation. Therefore, further research is required to clearly
examine the effects of glutamine supplementation on health
conditions in older people with poor health.
It has been observed that supplementation with more than 1 g/day
of vitamin C improves immunity in healthy adults.(24) Supple-
mentation with vitamin E in unhealthy subjects (750 mg/day)
and in healthy elderly subjects (800 mg/day) enhance their
immunity.(25,46) The amount of administered vitamins in this
study was smaller than that administered in the previous studies.
Although the contribution of individual substrates to the increased
NK cell activity was not identifiable, it may have partially influ-
enced NK cell activity. This issue should be resolved in future
researches.
In conclusion, this study suggested that dietary supplementation
with the amino acids arginine (500 mg/day), glutamine (600 mg/
day), leucine (1200 mg/day), and 11 kinds of vitamins for the
elderly in poor health increased NK cell activity, regardless of the
presence of a primary disease and the amount of the daily nutrient
intake. This supplementation may be useful for supporting innate
immunity and improving the health of these patients.
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